Oncogenic ACSM6 impairs CD8⁺ T cell-based immune response in bladder cancer.

In an extensive immunotherapy dataset encompassing diverse tumor types [ 11 ], although statistical significance was not definitively reached, a notable trend emerged, suggesting a correlation between elevated ACSM6 expression and reduced overall survival among patients undergoing immunotherapy.

also in 2,105 other papers